Global multiple myeloma therapies sector hits US$23.13 billion in 2024, targeting US$37.07 billion by 2033 at 5.4% CAGR. Uncover trends in CELMoDs (iberdomide), proteasome inhibitors, and ADCs like Blenrep, with 70% response rates from bispecifics driving frontline regimens. https://finance.yahoo.com/news/next-generation-multiple-myeloma-therapies-112000005.html